These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12673783)

  • 21. Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain.
    Delgado E;
    Int J Clin Pract; 2012 Mar; 66(3):281-8. PubMed ID: 22340448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P; Karlander S; Steen L; Efendic S
    Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC; Rosenstock J; Gerich J;
    Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin.
    Chan JY; Leyk M; Frier BM; Tan MH
    Diabetes Metab Res Rev; 2009 Mar; 25(3):224-31. PubMed ID: 19156705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M; Swatko A; Hilberg C; Shestakova M
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
    Chou HS; Palmer JP; Jones AR; Waterhouse B; Ferreira-Cornwell C; Krebs J; Goldstein BJ
    Diabetes Obes Metab; 2008 Aug; 10(8):626-37. PubMed ID: 17645558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D; Smirnova O; Christiansen JS; Kanc K; le Devehat C; Wojciechowska M; López de la Torre M; Liebl A
    Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M; Humburg E; Dressler A; Ziemen M
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Gallwitz B; Guzman J; Dotta F; Guerci B; Simó R; Basson BR; Festa A; Kiljański J; Sapin H; Trautmann M; Schernthaner G
    Lancet; 2012 Jun; 379(9833):2270-8. PubMed ID: 22683137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial.
    Fanelli CG; Pampanelli S; Porcellati F; Rossetti P; Brunetti P; Bolli GB
    Ann Intern Med; 2002 Apr; 136(7):504-14. PubMed ID: 11926785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
    Gallwitz B; Rosenstock J; Patel S; von Eynatten M; Hehnke U; Mehlburger L; Dugi KA; Woerle HJ
    Diabetes Obes Metab; 2015 Mar; 17(3):276-84. PubMed ID: 25425502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.